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Abstract
BMI1 is a key component of the PRC1 complex (polycomb repressive complex-1) required for 
maintenance of normal and cancer stem cells. Its aberrant expression is detected in chronic 
myeloid leukemia and Ph+ acute lymphoblastic leukemia (ALL), but no data exist on BMI1 
requirement in ALL cells.
We show here that BMI1 expression is important for proliferation and survival of Ph+ ALL cells 
and for leukemogenesis of Ph+ cells in vivo.
Levels of BIM, interferon-α (IFNα)-regulated genes, and E2F7 were upregulated in BMI1-
silenced cells, suggesting that repressing their expression is important for BMI1 biological effects. 
Consistent with this hypothesis, we found that: i) downregulation of BIM or E2F7 abrogated 
apoptosis or rescued, in part, the reduced proliferation and colony formation of BMI1 silenced 
BV173 cells; ii) BIM/E2F7-double silencing further enhanced colony formation and in vivo 
leukemogenesis of BMI1-silenced cells; iii) overexpression of BIM and E2F7 mimicked the effect 
of BMI1 silencing in BV173 and SUP-B15 cells and iv) treatment with IFNα suppressed 
proliferation and colony formation of Ph+ ALL cells.
These studies indicate that the growth-promoting effects of BMI1 in Ph+ ALL cells depend on 
suppression of multiple pathways and support the use of IFNα in the therapy of Ph+ ALL.
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p210 and p190BCR-ABL1 transform hematopoietic stem cells (HSCs) and/or committed 
lymphoid progenitors respectively, causing chronic myeloid leukemia (CML) and Ph+ ALL, 
two diseases markedly different in outcome and response to therapy (1). Transformation by 
BCR-ABL1 oncogenic proteins depends on their constitutive tyrosine kinase activity and 
rests on the ability to activate proliferative and survival signaling pathways essential for 
leukemogenesis such as RAS, PI-3K/AKT and STAT 5 (2–6). The tyrosine kinase activity of 
p190BCR-ABL1 is more potent than that of p210BCR-ABL1 (7); however, this does not 
explain the different outcome of CML and Ph+ ALL: 40–50% of Ph+ ALL patients express 
p210BCR-ABL1 and yet they may have slightly worse outcome of those expressing 
p190BCR-ABL1 (8,9). An explanation for the different clinical behavior of CML and Ph+ 
ALL may rest in the cell of origin of the disease as BCR-ABL1-transformed HSCs are less 
prone to secondary mutations than committed B-cell progenitors (5,10). Some, if not all, of 
the secondary mutations in Ph+ ALL may be caused by aberrant RAG-dependent 
recombination (i.e. deletion of IKAROS or the INK4A/ARF locus) and/or AID-dependent 
somatic hypermutation (mutation of BCL-6 or BCR-ABL1 itself) (11–13). Thus, inhibiting 
the BCR-ABL1 kinase is insufficient to eradicate most Ph+ ALL cell clones and alternative 
BCR-ABL1-dependent and independent pathways need to be targeted for an effective 
treatment of Ph+ ALL.
We recently found that the Polycomb group (PcG) family BMI1 gene (14) is required for the 
proliferation and colony formation of p190BCR-ABL1-transformed B cells (15).
The BMI1 protein functions as a key regulatory component of the PRC1 complex (16) and 
promotes the maintenance of normal and cancer stem cells (17–21). Aberrant expression of 
BMI1 is detected in several human malignancies (22), often correlating with metastatic 
disease and therapy failure (23–25).
Several findings support the importance of BMI1 in BCR-ABL1-positive leukemias, 
especially the lymphoid ones. First, BMI1 overexpression correlates with more advanced 
disease stages and with shorter time from CML-chronic phase to blast crisis (26, 27). 
Second, BMI1 collaborates with BCR-ABL1 in transformation of CD34 cord blood cells 
and these cells induce a transplantable leukemia in NOD/SCID mice with a predominant 
lymphoid immunophenotype (28). Third, ectopic expression of BMI1 in BCR-ABL1-
transformed HSCs enhanced the frequency of B-ALL-initiating cells in vitro and in mice, 
although BCR-ABL1 activity was still required for disease maintenance (29).
The oncogenic effects of BMI1 depend, in part, on silencing of the INK4A/ARF (CDKN2A) 
tumor suppressor locus that encodes the p16 (INK4A) and p14 (alternative reading frame, 
ARF) proteins (30,31). However, BMI1 can also exert its oncogenic effects through 
CDKN2A-independent pathways (32,33), but the precise mechanism(s) by which BMI1 
overexpression contributes to Ph+ ALL, especially in cases with deletion of the INK4A/ARF 
locus, have yet to be elucidated.
We show here that BMI1 is required for the proliferation, survival and maintenance of Ph+ 
ALL cells in vitro and in mice and that the effects are mediated, at least in part, through 
Mariani et al. Page 2

















Cell lines were tested for mycoplasma contamination (PCR Mycoplasma detection set, 
Takara Bio Inc., Japan) every 6 months. BV173 (CML- lymphoid blast crisis cell line) and 
SUP-B15 (Ph+ ALL cell line) cells were cultured in Iscove Modified Dulbecco’s Medium 
(Lonza Inc., Basel, Switzerland) supplemented with 10% heat-inactivated FBS, 1% 
penicillin- streptomycin, 1% L-glutamine, at 37°C, 5% CO2.
Primary Ph+ adult ALL (n=6) or CML-lymphoid blast crisis (n=1) cells derived from the 
peripheral blood (n=2) or the bone marrow (n=5) (average 77% blasts; range: 52–98%) were 
kindly provided by Dr Michael Caligiuri (Ohio State University, Columbus, OH) and Dr 
Martin Carroll (University of Pennsylvania, Philadelphia, PA) and were maintained in 
SFEM (Stem Cell Technology, Vancouver, Canada) supplemented with IL-3 (10 ng/ml), 
IL-7 (10 ng/ml), Flt3-L (20 ng/ml) and SCF (30 ng/ml) (ProSpec, Israel).
Short hairpin RNA plasmids and lentiviral infection
Control shRNA, shBMI1#1, shBMI1#2 (cloned into the inducible pLKO-Tet-On puromycin 
vector) and shBIM (cloned into the pLKO-Tet-On neomycin vector) were kindly provided 
by Dr. Jagani (34). shE2F7 (#1-4) lentiviral vectors were purchased from Applied Biological 
Materials (Richmond, Canada).
For lentiviral infections, infectious supernatant of 293T cells transiently transfected with the 
indicated plasmids was collected at 48 and 72 hours and used to infect BV173, SUP-B15 
and primary Ph+ ALL/CML-lymphoid blast crisis cells. 24 hours later, cells were subjected 
to antibiotic selection for 5 (puromycin; 3μg/ml) or 14 (G418; 400 mg/ml) days.
BIM or E2F7 ectopic expression in BV173 or SUP-B15 cells
The human BIM coding sequence was obtained by PCR from cDNA of BV173 cells with 
the following primers: Fw 5′-GTACTCTAGAATGGCAAAGCAACCTTCTGA-3′, Rv 5′-
TAGAGGATCCTCAATGCATTCTCCACACC-3′. The BIM sequence was then cloned in 
the GFP-pUltra plasmid (Addgene) at the XbaI and BamHI restriction enzyme sites.
The human E2F7 coding sequence was cloned from the mammalian Gene Collection p- 
pCR4-TOPO-Human E2F7 sequence-verified cDNA (MHS6278-213243493 glycerol stock 
from Dharmacon) by PCR using the following primers: Fw 5′-
AGTCTCTAGAATGGAGGTAAATTGTTTAACACTAAAA-3′, Rv 5′-
TACTGAATTCTTAGTCAGCGCCGCCG-3′. The E2F7 sequence was cloned in the GFP- 
pUltra plasmid at the XbaI and EcoRI restriction enzyme sites.
Three subsequent lentiviral infections were carried out as described above and 18 hours after 
the last infection, transduced cells were sorted based on GFP positivity and used for western 
blot and colony assays after 1–2 h recovery in fresh medium.
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Cell proliferation, cell cycle analysis and colony formation assay
Proliferation of shRNA-transduced BV173 and SUP-B15 cells was assessed by seeding 5 × 
104 cells/ml with or without doxycycline (Doxy, 2.5μg/ml; Research Product International, 
Mt. Prospect, IL, USA) and with or without imatinib (IM) (1μM added every 12h) (LC 
Laboratories, Woburn, MA, USA) and counting the cells every 24h by trypan blue exclusion.
Cell cycle analyses were performed by propidium iodide staining and sub-G1 cells were 
considered apoptotic.
For colony-formation assays, Ph+ cell lines transduced with different lentiviral shRNAs or 
treated with IFNα were plated in methylcellulose (Stem Cell Technologies) with or without 
2.5μg/ml Doxy (4 hours of pre-treatment in liquid culture and then added to the plates) and 
with or without imatinib (0.5–2μM). Colonies were counted 6 days later. Data shown 
represent the mean of technical triplicates of three independent experiments.
Ph+ ALL or CML-lymphoid blast crisis primary cells (lentivirus shRNA-transduced or drug-
treated) were plated in methylcellulose supplemented with IL-3, IL-6, IL-7, Flt3-L, and SCF 
at the concentrations indicated above and colonies were counted 10 days later.
Animals
Six-to-seven week-old NOD/SCID/IL-2Rγnull mice (The Jackson Laboratory, Sacramento, 
CA, USA) were intravenously injected with parental, scramble, BMI1shRNA-transduced 
BV173 or SUP15 cells, or BMI1/BIM/E2F7shRNA-transduced BV173 cells (2×106 cells/
mouse). Mice injected with parental cells were left untreated, while those injected with 
shRNA-BV173 or -SUP-B15 cells were continuously treated, starting 72 hours post-
injection, with Doxy (2g/L) in D(+)-sucrose-supplemented (30g/L) drinking water to induce 
BMI1 or BMI1 and BIM downregulation in vivo.
Experiments were performed according to Animal Care and Use Committee’s guidelines.
Sorting of leukemic cells from NSG mice
Leukemic mice were humanely euthanized and bone marrow cells were purified and stained 
with PE-anti-human CD10 Antibody (BD Pharmingen, Franklin Lakes, NJ, USA). Dead 
cells were excluded by DAPI staining and cells were then sorted based on PE positivity 
using a BD FACS Aria.
Real-time quantitative PCR analyses
For real-time quantitative PCR (qPCR), total RNA was isolated from BV173-sh scramble, 
BV173-shBMI1#1 cells using the RNeasy Plus Mini kit (Qiagen, Limburg, The 
Netherlands) and reverse-transcribed (2 μg) the High-Capacity cDNA Reverse Transcription 
Kit (ThermoFisher Scientific, Waltham, MA USA. First-strand cDNA was used as PCR 
template. Reactions were done in triplicate, and RNA extracted from 2 separate experiments.
Primers used were: IFI6 Fw: 5′-GGTGGAGGCAGGTAAGAAAAAG-3′; IFI6 Rv: 5′-
GAGATAC TTGTGGGTGGCGT-3′; IFI44 Fw: 5′-AGGGAGTTGGTAAACGCTGG-3′; 
IFI44 Rv: 5′-TCCT CCCTTAGATTCCCTATTTGC-3′; IRF9 Fw: 5′-
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AGAAAGGGGCGGAGAGATCA-3′; IRF9 Rv: 5′-TGCCATCCTGAGTTGCTGTC-3′; 
OAS1 Fw: 5′-AACCCAGGCCTGTGATCCTG-3′; OAS1 Rv: 5′-
GGATCGTCGGTCTCATCGTC-3′; IFIT1 Fw: 5′-TGGGCCTTGCTGAAGTGTGGA-3′; 
IFIT1 Rv: 5′-AGCCATCCAGGCGATAGGCAG-3′; IFIT3 Fw: 5′-
CACAGACCTAACAGCACC CT-3′; IFIT3 Rv: 5′-
GACCTCACTCATGATGGCTGTTTC-3′; E2F7 Fw: 5′-CAGAACCGAGCAGCCCGTA; 
E2F7 Rv: 5′-TGCTTGATGGAGGCACCACT-3′
Microarray Analysis
Total RNA was isolated from BV173 shBMI1#1 cells, untreated or treated with Doxy (2.5 
μg/ml), purified with RNeasy Column (Qiagen) and used (5μg) to generate biotin-labeled 
cRNA using an oligo T7 primer in a reverse transcription reaction followed by in vitro 
transcription reaction with biotin labeled UTP and CTP. 10 μg of cRNA were fragmented 
and hybridized to HuGene 2.0 chip (Affymetrix, Santa Clara, CA). Hybridized arrays were 
stained according to the manufacturer’s protocols on a Fluidics Station 450 and scanned on 
an Affymetrix scanner 3000. Signal values were determined using the Gene Chip Operating 
System 1.0 (GCOS, Affymetrix). For identification of genes associated with specific 
biological processes, we used EPLtool, an automatic gene clustering tool developed by 
Wyeth Bioinformatics for Affymetrix qualifiers and Ingenuity Pathway Analysis (Qiagen).
Western Blotting
Antibodies used were: anti-BMI1 (ab38295, Abcam, Cambridge, MA, USA), anti BIM 
(H-191), anti β-ACTIN (C4), anti HSP90 (4F10) and anti-GRB2 (C23), all purchased from 
Santa Cruz Biotechnology (Dallas, TX, USA), and anti-E2F7 (ab56022, Abcam).
Statistical analyses
Data (means + SD, 3 experiments) were analyzed for statistical significance by unpaired, 2-
tailed Student t test or by One way Anova. P < 0.05 was considered statistically significant. 
Kaplan-Meier plots for mice survival experiments were generated using Graphpad Prism 
software. Statistical significance of differences in survival of mice injected with control, 
BMI1-silenced, or BMI1/BIM/E2F-7-silenced BV173 cells was assessed by log rank test.
Results
Proliferation, survival and colony formation is markedly suppressed in BMI1-silenced Ph+ 
ALL cells
In a previous study (15), we showed that proliferation and colony formation of SUP-B15 and 
Z-181 Ph+ ALL cell lines, in which BMI1 expression was downregulated by BMI1 siRNAs, 
was markedly suppressed compared to scramble siRNA-transfected cells. To further assess 
the requirement of BMI1 expression in Ph+ ALL cells and to investigate the underlying 
mechanisms, we generated two cell lines (BV173 and SUP-B15) expressing doxycycline-
inducible Bmi-1 shRNAs (#1 and #2) shown to inhibit Bmi-1 expression in multiple 
myeloma cells (34). In BV173 cells, BMI1 expression was markedly decreased after a 48h 
treatment with doxycycline and was almost undetectable at 72 or 96h (Supplementary Fig. 
1A).
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Downregulation of BMI1 expression induced a decrease of viable (trypan blue-negative) 
BV173 cells, especially evident after a 7-day doxycycline treatment (Supplementary Fig. 
1B). DNA content analysis of BMI1-silenced cells revealed an increase of sub-G1, apoptotic 
cells and, especially in shBMI1#2 BV173 cells, a marked decrease of S and G2 phase cells 
(Supplementary Fig. 1C). The increase in apoptotic cells was especially evident after a 96h 
treatment with doxycycline, a time point at which BMI1 expression was essentially 
undetectable. The effect of BMI1 silencing was also assessed by methylcellulose colony 
formation assays; as shown in Supplementary Fig. 1D, BMI1-silenced BV173 cells were 
markedly less clonogenic than the doxycycline-treated controls.
Cell counts and colony formation of BMI1-silenced SUP-B15 cells were significantly 
decreased compared to controls (Supplementary Fig. 2A and B); however, the decrease in 
colony formation was less striking than in BV173 cells (Supplementary Fig. 1D), probably 
reflecting incomplete BMI1 downregulation (Supplementary Fig. 2C).
An increase in apoptotic cells was also noted in BMI1-silenced SUP-B15 cells 
Supplementary Fig. 2D); consistent with the results of all other assays, apoptosis was also 
lower than in BV173 cells.
We also tested if BMI1 silencing (Fig. 1A; example of BMI1 downregulation in sample ALL 
#674) suppressed colony formation of primary Ph+ ALL cells; for these experiments, 
primary Ph+ ALL cells were transduced with the doxycycline-inducible BMI1 ShRNA 
lentiviruses and plated in methylcellulose in the presence of puromycin alone or puromycin 
and doxycycline. Colonies were counted 10 days later. Colony formation of doxycycline-
treated BMI1 shRNA-transduced cells was lower than that of the corresponding untreated 
cells (n=4) (Fig. 1B), in agreement with the effects in the Ph+ ALL cell lines.
Since imatinib treatment had no effect on the expression of BMI1 in BV173 cells (Fig 2A), 
we also assessed whether BMI1 silencing enhanced the inhibitory effect of imatinib on 
proliferation and colony formation of BV173 cells. Treatment with imatinib or with 
doxycycline markedly reduced the number of shBMI1#1 and #2-transduced BV173 cells 
compared to control cells especially after 7 days of treatment (Fig. 2B); however, co-
treatment with imatinib and doxycycline further reduced the number of shBMI1#1 and #2 
BV173 cells after 7 days of co-treatment (Fig. 2B).
Likewise, co-treatment with imatinib and Doxy was more inhibitory than either treatment on 
colony formation of shBMI1#1 or #2 BV173 cells (Fig. 2C). Same effects were observed in 
shBMI1 SUP-B15 cells (Supplementary Fig. 3), suggesting that imatinib treatment and 
BMI1 silencing suppress proliferation of BV173 and SUP-B15 cells through non-
overlapping pathways.
BMI1 silencing suppresses in vivo growth of BV173 and SUP-B15 cells
To determine whether BMI1 expression is also necessary for in vivo growth of BV173 and 
SUP-B15 cells, NOD/SCID/IL-2Rγnull (NSG) mice were intravenously injected with 
parental, scramble or shBMI1-transduced BV173 cells (2 × 106 cells/mouse) or with 
shBmi-1-transduced SUP-B15 cells. Mice injected with parental cells were left untreated, 
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while those injected with scramble or shBMI1-BV173 cells were continuously treated, 
starting 72 hours post-injection, with Doxy in the drinking water to induce BMI1 
downregulation in vivo. Mice injected with parental or shscramble BV173 cells (n=10; 5 
mice/group) were all dead after 65 days and there was no difference in the survival of 
untreated and Doxy-treated mice (Fig. 3A); by contrast, mice injected with shBMI1 (#1 or 
#2) BV173 cells and treated with doxycycline (n=14; 7 mice/group) survived much longer 
(approximately 128 days) (P<0.0001) than the control mice (Fig. 3A), indicating that BMI1-
regulated pathways are required for in vivo growth of BV173 cells. To assess whether death 
of the mice was due to the outgrowth of leukemic cells in which BMI1 expression was no 
longer silenced, terminally ill mice (n=3) injected with scramble or shBMI1 BV173 cells 
and continuously treated with doxycycline were sacrificed and CD10+ (BV173) cells were 
isolated from the bone marrow and lysed to assess BMI1 levels. Anti-BMI1 western blotting 
of CD10+ cell lysates revealed that BMI1 expression remained silenced upon doxycycline 
treatment of mice injected with shBMI1 BV173 cells (Fig. 3B), suggesting that, by itself, 
BMI1 silencing can slow down but not suppress entirely the process of leukemia.
The effect of BMI1 silencing for in vivo leukemogenesis was also assessed in NSG mice 
injected with shBMI1 SUP-B15 cells. In this model, the five mice left untreated were all 
dead after 61 days; by contrast, the Doxy-treated mice (n=5) survived much longer (mean 
survival of 97 days) (P=0.0017) (Fig. 3C). Persistence of BMI1 downregulation was also 
noted in CD19+ cells isolated from a terminally ill doxycycline-treated mouse injected with 
SUP-B15 cells (data not shown).
Downregulation of BIM expression rescues apoptosis but not the impaired colony 
formation of BMI1-silenced BV173 cells
The CDKN2A locus, which is a target of BMI1-dependent repression, is deleted in the Ph+ 
ALL cell lines used in this study (35) which do not express p16INK4A or p14ARF (not 
shown). Thus, the growth-inhibitory effects of BMI1 silencing in BV173 cells are INK4A/
ARF-independent. Previous studies in BMI1-silenced myeloma lines showed that expression 
of pro-apoptotic BIM is upregulated and that inhibition of BIM expression rescued, in part, 
the enhanced apoptosis of these cells (34). Thus, we assessed BMI1-dependent expression 
and requirement of BIM in BV173 cells; as shown in Fig. 4A, expression of BIM was 
upregulated in BMI1-silenced BV173. Thus, BV173 cells were transduced with three 
doxycycline-inducible BIM shRNA lentiviruses and selected in the presence of G418; 
western blot analysis of Doxy-treated cells revealed that BIM expression was downregulated 
only in cells transduced with the BIM shRNA#1 lentivirus (Supplementary Fig 4A). 
Proliferation and colony formation assays of double-silenced BMI1/BIM BV173 cells 
showed that cell numbers and methylcellulose colonies were identical to those of BMI1-
silenced cells (Fig. 4B and 4C) or BMI1-silenced/scramble-transduced cells (not shown), 
indicating that enhanced expression of BIM alone cannot explain the impaired growth of 
BMI1-silenced BV173 cells.
However, DNA content analysis of BMI1- and BMI1/BIM-silenced BV173 cells showed 
that apoptosis susceptibility (sub-G1 fraction) of BMI1-silenced cells was completely 
rescued by BIM downregulation (Fig 4D and Supplementary Fig. 4B), indicating that BMI1 
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regulates proliferation and survival of BV173 cells through different effectors. Of interest, 
BMI1/BIM-silenced cells exhibited an increased percentage of G1 cells which was not 
evident in BMI1-silenced BV173 cells (Supplementary Fig. 1); this observation probably 
reflects the increased apoptosis of these cells (Supplementary Fig. 1) compared to 
BMI1/BIM double-silenced cells in which apoptosis is completely abrogated (Fig. 4D). The 
accumulation of BMI1/BIM double-silenced cells in the G1 phase of the cell cycle likely 
explains why BIM silencing did not rescue the proliferation and colony formation of 
shBMI1-silenced BV173 cells.
BMI1 silencing enhances the expression of interferon-α-regulated genes and E2F7
To search for INK4A/ARF- and BIM-independent pathways involved in cell cycle regulation 
that may explain the growth inhibition of BMI1-silenced Ph+ ALL cells, we assessed the 
gene expression profile of BMI1-silenced BV173 cells. For these experiments, total RNA 
was isolated from untreated or Doxy-treated (48h) shBMI1#1 BV173 cells and used for 
oligonucleotide microarray hybridization to identify global changes in gene expression 
resulting from BMI1 knockdown. Treatment with doxycycline almost abolished BMI1 
expression (not shown); the majority (69 out of 115) of genes showing a > 2-fold change in 
expression upon BMI1 silencing were upregulated, consistent with the transcription 
repression function of BMI1; among the 836 genes showing at least a 1.5 fold change in 
expression in Doxy-treated ShBmi-1#1 BV173 versus the untreated control (FDR<0.05), 
380 were also downregulated, possibly via indirect mechanisms. Many IFNα-regulated 
genes and E2F7 were among those upregulated in BMI1-silenced cells (Supplementary 
Table 1). The volcano plot of differential expression analysis shows that most genes were 
centered around zero, confirming the correct normalization of the datasets (Supplementary 
Figure 5A).
Moreover, hierarchical clustering of differentially expressed genes in the two biological 
replicates of Doxy-treated versus untreated shBMI1#1 BV173 cells suggests that the two 
samples have distinct gene signatures (Supplementary Figure 5B). To assess the top 
canonical pathways enriched in BMI1-silenced cells, we performed Ingenuity Pathway 
Analysis (www.ingenuity.com) on differentially expressed genes and found that the second 
most enriched pathway was that of the IFNα response (Supplementary Figure 6). To further 
confirm this finding, changes in the expression of IFIT3 (interferon-induced protein with 
tetratricopeptide repeats 3), IRF-9 (interferon regulatory factor 9), IFI44 (interferon induced 
44), IFI6 (interferon induced 6), IFIT1 ((interferon-induced protein with tetratricopeptide 
repeats 1), 2′-5′ oligoadenylate synthetase 1 (OAS1) and E2F7 were validated by real time 
PCR (Supplementary Fig. 7).
E2F7 or E2F7/BIM downregulation rescues, in part or almost entirely, the growth inhibition 
of BMI1-silenced BV173 cells
E2F7 inhibits cell proliferation by binding multiple G1/S- regulated genes and repressing 
their transcription and by interacting with E2F1 and blocking its transcription-activation 
function (36,37). Thus, we assessed whether the impaired proliferation of BMI1-silenced 
BV173 cells could be rescued by E2F7 silencing. Real-time PCR of shBMI1 BV173 cells 
transduced with different shE2F7/GFP lentiviruses revealed that E2F7 expression was 
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downregulated only in cells transduced with the hE2F7/GFP#3lentivirus (Supplementary 
Fig. 8). Proliferation and colony formation assays of double-silenced BMI1/E2F7 BV173 
cells showed that cell numbers and methylcellulose colonies were more numerous than those 
of BMI1-silenced cells (Fig. 5A and 5B), suggesting that enhanced expression of E2F7 can, 
in part, explain the impaired growth of BMI1-silenced BV173 cells; by contrast, apoptosis 
susceptibility (sub-G1 fraction) of BMI1-silenced cells was not rescued by E2F7 
downregulation (not shown).
Since BIM silencing did not enhance the proliferation but completely blocked the apoptosis 
of BMI1-silenced BV173 cells (Fig. 4), we also assessed the effects of simultaneous 
downregulation of BIM and E2F7 in BMI1-silenced cells. BIM/E2F7 downregulation 
rescued almost entirely the reduced colony formation and cell growth of BMI1-silenced 
BV173 cells (Fig. 5B and C), but the size of the colonies was smaller than that of untreated 
shBMI1/BIM/E2F-7 BV173 cells (not shown); as expected, BMI1/BIM/E2F-7-silenced 
BV173 cells did not undergo apoptosis (not shown).
To determine whether the molecular interplay among BMI1, BIM and E2F7 exists also in 
primary cells, we assessed the expression of BIM and E2F7 in BMI1-silenced Ph+ ALL 
cells and found increased expression of both compared to control cells (Fig 6A, ALL#1222 
is shown as example).
Moreover, Doxy-treated NSG mice injected with shBMI1/BIM/E2F7 BV173 cells (n=7) 
exhibited a shorter survival than Doxy-treated mice injected with shBMI1 BV173 cells 
(median survival of 94.5 vs 128 days; P= 0.0042) (Fig. 6B). By contrast, survival of 
untreated mice injected with shBMI1/BIM/E2F7 BV173 cells (n=3) was 60 days (Fig. 6B), 
undistinguishable from that of mice injected with parental BV173 cells or Doxy-treated 
mice injected with shscr BV173 cells (Fig. 3A).
BIM or E2F7 overexpression mimics the effect of BMI1 silencing on colony formation of 
BV173 cells
To further assess whether BIM and E2F7 are, at least in part, responsible for the biological 
effects of BMI1 silencing, BV173 or SUP-B15 cells were transduced with a pUltra lentivirus 
driving BIM or E2F7 expression, sorted by GFP positivity, and plated in methylcellulose. 
Compared to controls, BV173 cells transduced with the pUltra-BIM or the pUltra-E2F7 
vector exhibited high levels of ectopic BIM or E2F7 expression (Fig. 7A) and were 
markedly less clonogenic (Fig. 7B and C). Similar results were obtained in pUltra-BIM- or 
pUltra-E2F7- transduced SUP-B15 cells (Supplementary Fig. 9).
IFNα treatment inhibits colony formation of Ph+ ALL cells
Since microarray analysis of BMI1-silenced BV173 cells revealed increased expression of 
IFNα regulated genes (Supplemetary Table 1), and the activation of this pathway may be 
also important for the growth inhibition of BMI1-silenced BV173 cells, we performed 
colony formation assays of IFNα-treated Ph+ ALL cells. As shown in Fig 8A, treatment 
with INFα inhibited colony formation of BV173 cells and this effect was enhanced by co-
treatment with imatinib. Moreover, colonies derived from IFNα-treated BV173 cells were 
smaller than those derived from untreated cells (192 ± 11 vs 308 ± 48 cells/colony, 
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respectively) and colonies from BV173 cells treated with IFNα and imatinib were smaller 
than those from cells treated with imatinib only (37 ± 6 vs 47.5 ± 2 cells/colony). Of greater 
importance, treatment with IFNα markedly suppressed colony formation of primary Ph+ 
ALL samples (n=4) (Fig. 8B and C), and the effect was further increased by co-treatment 
with imatinib (n=3) (Fig. 8B) or dasatinib in a sample insensitive to imatinib (Fig. 8C).
The effects of BMI1 silencing are, in part, mimicked by treatment with the BMI1 inhibitor 
PTC-209
A small molecule inhibitor of BMI1, PTC-209, has recently been described and shown to 
inhibit the self-renewal of colorectal cancer-initiating cells resulting in suppression of tumor 
growth (38). Thus, we tested whether treatment of Ph+ ALL cells with PTC-209 would 
mimic the effects of BMI1 silencing. As shown in Supplementary Fig. 10, treatment with 
PTC-209 markedly suppressed proliferation and colony formation of Ph+ BV173 cells 
(panels A and B) and colony formation of Ph+ primary ALL cells (panel C). Analysis of 
BMI1 and BMI1 target expression revealed that BMI1 levels were reduced after a 48–72 h 
treatment specially at the 10μM drug concentration (panel D), while inhibition of 
proliferation and colony formation was observed also at the 1μM (panels A and B) and 
0.5μM (not shown) concentrations; of interest, expression of BIM showed a steady increase 
starting at 16 h during the 3–72 h PTC-209 treatment (panel D), while RNA levels of BMI1-
regulated BIM, IFNα-response genes and E2F7 in PTC-209-treated cells showed no changes 
or were different from those in BMI1-silenced cells (compare Supplementary Fig. 7 and 
Supplementary Fig. 10, panel E).
Discussion
We show here that BMI1, a component of the Polycomb-repressive complex 1 essential for 
stem cell maintenance in many cell types, is required for proliferation, survival and 
leukemogenesis of Ph+ ALL cells.
In particular, BMI1-silenced Ph+ ALL cells proliferated less, formed fewer colonies, and 
exhibited enhanced sensitivity to imatinib treatment than control cells; and NSG mice 
injected with Tet-On-shBMI1 BV173 or SUP-B15 cells and treated with Doxy to silence 
BMI1 expression exhibited markedly prolonged survival, compared to control mice.
Of interest, ALL cells sorted from the bone marrow of terminally ill Doxy-treated mice 
revealed persistent downregulation of BMI1 expression, indicating that silencing BMI1 
alone can only delay the process of leukemogenesis and/or that Ph+ ALL cells may escape 
BMI1 inhibition through the activation of other growth-promoting pathways.
BMI1 expression is known to promote tumorigenesis through transcriptional silencing of 
ARF (p14) and INK4A (p16) expression (30,31). However, the INK4A/ARF locus is 
homozygously deleted in the cell lines and in some of the primary Ph+ ALL samples used 
here, strongly suggesting that BMI1 is required by Ph+ ALL cells through INK4A/ARF-
independent pathways (32,33). In multiple myeloma cells, the growth-promoting effects of 
BMI1 were also INK4A/ARF-independent and were, in part, mediated through repression of 
the pro-apoptotic BIM gene (34).
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Consistent with these findings, expression of BIM was also enhanced in BMI-silenced 
BV173 cells and Ph+ primary ALL cells. However, downregulating BIM expression 
abolished the apoptosis of BMI1 silenced cells, but did not rescue their impaired 
proliferation and colony formation, most likely because of an increase in the fraction of G1 
phase cells.
Therefore, we searched for novel BMI1-regulated genes whose modulation may explain the 
reduced proliferation of Ph+ ALL cells through INK4A/ARF-independent mechanisms. Of 
interest, expression of E2F7, a member of the E2F family with cell cycle inhibitory activity 
(36,37), and of many IFNα-responsive genes was upregulated in BMI1-silenced cells, 
raising the possibility that the effects of BMI1 may be due, in part, to repression of E2F7- 
and/or IFNα-regulated pathways. Indeed, E2F7 downregulation reversed, in part, the 
inhibition of cell proliferation and colony formation induced by BMI1 silencing, but 
apoptosis susceptibility of BMI1/E2F7-silenced cells was only rescued when BIM 
expression was also downregulated; moreover, E2F7/BIM downregulation accelerated the 
leukemogenesis of shBMI1-silenced BV173 cells, further confirming that BMI1 promotes 
cell growth and survival of Ph+ ALL cells through distinct pathways. In addition, 
overexpression of BIM or E2F7 in BV173 and SUP-B15 cells mimicked the effects of BMI1 
silencing.
The observation that BMI1 silencing induced the upregulation of many IFNα-response 
genes suggests that the growth-promoting effects of BMI1 in Ph+ ALL cells may also 
depend, at least in part, on negative regulation of the IFNα-response pathway, providing a 
rationale for targeting this pathway. Indeed, treatment with IFNα inhibited the colony 
formation of primary Ph+ ALL cells and this effect was enhanced by co-treatment with 
imatinib or dasatinib; these findings support a therapeutic strategy for Ph+ ALL 
simultaneously targeting the BCR-ABL1 tyrosine kinase and harnessing the growth-
suppressive effects of IFNα.
Despite recent improvements through integrated therapeutic approaches consisting of 
tyrosine kinase inhibitors (TKIs), stem cell transplantation (SCT) and chemotherapy (39), 
most Ph+ ALL patients still have a poor outcome because of the rapid development of 
resistance to TKIs (40,41).
Few pilot studies that examined the effects of concomitant administration of IFNα with 
TKIs, chemotherapy or SCT in patients with Ph+ ALL have reported encouraging results 
(42–44); however, larger patients’ cohorts and longer follow-ups are necessary to determine 
whether IFNα has a useful role in the therapy of Ph+ ALL.
Although targeting specific BMI1-regulated pathways may be a useful approach for the 
therapy of Ph+ ALL, direct inhibitors of BMI1 may prove far better therapeutic agents due 
to the ability to activate the full spectrum of BMI1-regulated growth-suppressive pathways.
In experiments using PTC-209, a recently discovered BMI1 small molecule inhibitor (38), 
we found that it markedly suppressed the growth of Ph+ BV173 cells and primary Ph+ ALL 
cells (Supplementary Fig. 10). However, the effects were observed at drug concentrations 
that did not significantly reduce BMI1 levels and the expression of BMI1-regulated genes, 
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although PTC-209 treatment induced BIM expression. The reason for these apparently 
contradictory findings is unclear since PTC-209 was identified in a high-throughput 
screening of compounds inhibiting Luciferase activity regulated by the BMI1 5′ and 3′ 
untranslated (UTR) regions (38), implying that decreased BMI1 expression is the primary 
mechanism of action of PTC-209. In a recent study (45), treatment with PTC-209 led to a 
clear decrease of BMI1 expression in CML cells; this observation suggests that the 
difference with our findings in Ph+ ALL cells may be, perhaps, explained by cell type-
specific effects influencing levels and/or kinetics of BMI1 and BMI1 targets expression in 
response to PTC-209. It is also possible that the effects of PTC-209 in Ph+ ALL cells may 
be, in part, BMI1-independent.
In summary, we have shown here that BMI1 expression is required by Ph+ ALL cells and 
we have identified novel targets that appear to be mechanistically involved in its growth-
promoting effects. Targeting BMI1 or essential BMI1-regulated pathways has the potential 
to improve the outcome of Ph+ ALL patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. BMI1 downregulation inhibits colony formation of Ph+ ALL primary cells
(A) BMI1 levels in ALL# 674 cells transduced with the shBMI1 #1 lentivirus; (B) 
methylcellulose colony formation (mean + SD of four independent experiments) of 
untreated or Doxy-treated (2.5μg/ml) parental, shBMI1#1- or shBMI1#2-transduced 
peripheral blood (n=2) or bone marrow (n=2) derived Ph+ ALL cells. Colonies were counted 
10 days after seeding 4 × 104 cells/plate.
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Fig. 2. BMI1 silencing enhances imatinib-induced inhibition of cell proliferation and colony 
formation of BV173 cells
(A) Western blot shows BMI1 expression in imatinib (IM)- or Doxy-treated shBMI1 BV173 
cells; (B) cell counts at 168h post treatment or (C) colony formation of untreated shBMI1 
BV173 cells or cells treated with Doxy (2.5μg/ml), IM (1μM), or the Doxy/IM combination. 
Data represent the mean + SD of three independent experiments. Statistical analysis: one 
way Anova with Bonferroni’s correction. *<0.05.
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Fig. 3. BMI1 inhibition suppresses growth of BV173 or SUP-B15 cells in NSG mice
(A, C) Kaplan-Meier plots show survival of NSG mice injected with 2×106 parental, 
scramble, or shBMI1 silenced (shBMI1 #1 and #2) BV173 (A) or SUP-B15 (C) cells. Mice 
injected with parental cells were left untreated while those injected with scramble, shBMI1 
#1 and #2 BV173 cells or shBMI1 SUP-B15 cells were continuously treated with Doxy in 
the drinking water (2 g/L) starting three days post-cell injection. (B) Expression of BMI1 in 
CD10-cALLA+ cells sorted from the bone marrow of 3 leukemic NSG mice injected with 
shScr BV173 (ShScr) or with shBmi-1 BV173 cells (ShBmi-1). GRB2 expression was used 
as loading control.
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Fig. 4. BIM silencing rescues apoptosis but not the BMI1-mediated inhibition of cell proliferation 
and colony formation of BV173 cells
(A) Western blot shows expression of BIM in untreated or Doxy-treated (2.5μg/ml; 72 h) 
shScr or shBMI1-transduced BV173 cells (A); HSP90 expression was examined as loading 
control. (B) Cell counts, (C) methylcellulose colonies, and (D) % apoptosis (mean+ SD of 
three independent experiments) of untreated or Doxy-treated shBMI1/ShBIM BV173 cells. 
Statistical analysis: one way Anova with Bonferroni’s correction. **<0.01, ***<0.001.
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Fig. 5. Effect of E2F7 or E2F7/BIM silencing on BMI1-dependent inhibition of proliferation and 
survival of BV173 cells
Cell counts (A, C) and colony formation (B) (mean SD of three independent experiments) of 
untreated or doxycycline-treated shBMI1, double-transduced-shBMI1/shE2F7, or triple-
transduced shBMI1/shBIM/shE2F7 BV173 cells. Statistical analysis: one way Anova with 
Bonferroni’s correction. *<0.05, **<0.01, ***<0.001.
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Fig. 6. E2F7 and BIM are BMI1 targets in Ph+ ALL primary cells and E2F7/BIM silencing 
rescues, in part, the leukemogenesis of BMI1-silenced BV173 cells in NSG mice
(A) Western blot shows the increased expression of BIM and E2F7 in Ph+ ALL#1222 
patient derived primary cells. βACTIN is shown as loading control.
(B) Kaplan-Meier plot shows survival of NSG mice injected with 2×106 untreated or Doxy-
treated BIM/E2F7-silenced shBMI1-BV173 cells. In the Doxy-treated group, mice were 
continuously treated with Doxy in the drinking water (2 g/L) starting three days post-cell 
injection. Survival curves of Doxy treated mice injected with shBMI1-BV173 cells are 
shown as control. Statistical analysis: log rank test..
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Fig. 7. Overexpression of BIM or E2F7 suppresses colony formation of BV173 cells
(A) Western blots show overexpression of BIM or E2F7 in pUltra-BIM- or pUltra-E2F7-
transduced BV173 cells. βACTIN expression is shown as loading control; (B, C) Colony 
formation of pUltra-BIM (B) or pUltra-E2F7 (C)-transduced BV173 cells. Data represent 
the mean + SD of two independent experiments. Statistical analysis: 2-tailed Student t test. 
***<0.001
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Fig. 8. Effect of IFNα- and/or imatinib or dasatinib on colony formation of Ph+ ALL
Methylcellulose colony formation of BV173 (mean+ SD of three independent experiments) 
or primary bone marrow Ph+ ALL cells (mean+ SD of triplicate plates) treated with IFNα 
and/or imatinib (A and B, respectively) or with the IFNα and/or dasatinib (C). In (B), four 
samples were treated with IFNα only while three samples were treated with imatinib alone 
or the IFNα/imatinib combination. Results are expressed as % inhibition of colony 
formation of untreated vs treated cells. Statistical analysis: one way Anova with 
Bonferroni’s correction. **<0.01, ***<0.001.
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